• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vincerx Pharma Inc. (Amendment)

    2/13/24 4:55:33 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VINC alert in real time by email
    SC 13G/A 1 vincerx_sch13ga-021324.htm AMENDMENT TO FORM SC 13G
     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

    Vincerx Pharma, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    92731L106

    (CUSIP Number)

     

     

    Michael Hirschberg, Esq.

    Reitler Kailas & Rosenblatt LLP

    885 Third Avenue, 20th Floor

    New York, NY 10022

     

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐  Rule 13d-1(b)
    ☒  Rule 13d-1(c)
    ☐  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No. 92731L106   13G   Page 2 of 7 Pages

     

             
    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Affinity Healthcare Fund, LP (EIN 82-1629802)

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
       
    3.   SEC USE ONLY
     
       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

       
             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.

     

     

     

    SOLE VOTING POWER
     

    0

      6.  

    SHARED VOTING POWER

     

    0
     

      7.  

    SOLE DISPOSITIVE POWER
     

    0

      8.  

    SHARED DISPOSITIVE POWER

     

    0
     

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) ☐
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0
       
    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

       

     

     
     

     

    CUSIP No. 92731L106   13G   Page 3 of 7 Pages

     

             
    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Affinity Asset Advisors, LLC (EIN 82-1567490)

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a) ☐
    (b) ☐
       
    3.   SEC USE ONLY
     
       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

       
             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

     

    0
     

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.  

    SHARED DISPOSITIVE POWER

     

    0 

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) ☐
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0
       
    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

       
             

     

     
     

     

    CUSIP No. 92731L106   13G   Page 4 of 7 Pages

     

    Item 1.

      (a)

    Name of Issuer:

    Vincerx Pharma, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices:

    260 Sheridan Avenue, Suite 400

    Palo Alto, CA 94306

     

    Item 2.

      (a)

    Name of Persons Filing:

    Affinity Healthcare Fund, LP
    Affinity Asset Advisors, LLC

         
      (b)

    Address of Principal Business Office or, if None, Residence:

    767 Third Avenue, 15th Floor

    New York, NY 10017

         
      (c)

    Citizenship:

    Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware

     

         
      (d)

    Title of Class of Securities:

    Common Stock, par value $0.0001 per share

         
      (e)

    CUSIP Number:

     

    92731L106

     
     

     

    CUSIP No. 92731L106   13G   Page 5 of 7 Pages

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ¨

    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     
     

     

    CUSIP No. 92731L106   13G   Page 6 of 7 Pages

     

    Item 4.  Ownership.

    See Items 5, 6, 7, 8 and 9 of each cover page.

    Item 5.  Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8.  Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9.  Notice of Dissolution of Group.

     

    Not Applicable

     

    Item 10.  Certification.

     

    By signing below, we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    CUSIP No. 92731L106   13G   Page 7 of 7 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 13, 2024

    Date

       
     

    Affinity Healthcare Fund, LP

       
       
     

    By: /s/ Michael Cho

    Signature

     

    AFFINITY ASSET ADVISORS, LLC

     

    By: /s/ Michael Cho

    Signature

       
       

     

     

     

    Get the next $VINC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VINC

    DatePrice TargetRatingAnalyst
    1/14/2022$25.00Buy
    HC Wainwright & Co.
    12/23/2021$25.00Overweight
    Cantor Fitzgerald
    11/1/2021$24.00Outperform
    SVB Leerink
    9/13/2021$30.00Buy
    Laidlaw
    8/25/2021$26.00Buy
    B. Riley Securities
    8/13/2021$33.00 → $30.00Buy
    Chardan Capital
    More analyst ratings

    $VINC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vincerx Pharma Inc.

    SCHEDULE 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    7/29/25 5:55:43 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Vincerx Pharma Inc.

    DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)

    7/16/25 4:14:14 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Vincerx Pharma Inc.

    DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)

    7/7/25 4:27:01 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

    Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal on a timely basis will result in continued operating costs and further reduce or eliminate any potential distributions to stockholders   SAN MATEO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the re-convened Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has again been adjourned, this time until 10:00 a.m., Pacific time, on August 27, 2025 via li

    7/16/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

    Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders   SAN MATEO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced updated information regarding the Special Meeting of Stockholders of the Company (the "Special Meeting") to consider the proposal to approve the dissolution and liquidation of the Company pursuant to the Plan of Liquidation and Dissolution (the "Dissolution Proposal"). The Special Meeting was adjourned to 10:0

    7/7/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

    SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal. Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal. Vincerx's board of directors unanimously recommends that stoc

    6/18/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Vincerx Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00

    1/14/22 6:06:29 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vincerx Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00

    12/23/21 6:37:41 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink initiated coverage on Vincerx Pharma with a new price target

    SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00

    11/1/21 6:31:16 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Haas Kevin claimed ownership of 42,776 shares (SEC Form 3)

    3 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    1/6/25 4:29:47 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Thomas Tom C

    4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    8/14/24 8:11:28 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Hamdy Ahmed Md

    4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    8/14/24 8:07:30 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 11:57:03 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/13/24 8:32:26 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care